Login / Signup

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.

Emanuel Della-TorreCampochiaro CorradoGiulio CavalliGiacomo De LucaAngela NapolitanoSalvatore La MarcaNicola BoffiniValentina Da PratGaetano Di TerlizziMarco LanzillottaPatrizia Rovere QueriniAnnalisa RuggeriGiovanni LandoniMoreno TresoldiFabio CiceriALberto ZangrilloFrancesco De CobelliLorenzo Dagnanull nullnull null
Published in: Annals of the rheumatic diseases (2020)
At day 28, overall clinical improvement and mortality in patients with severe COVID-19 were not significantly different between sarilumab and standard of care. Sarilumab was associated with faster recovery in a subset of patients showing minor lung consolidation at baseline.
Keyphrases